These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 39142498)

  • 1. Suppressive immune microenvironment and CART therapy for glioblastoma: Future prospects and challenges.
    Lu J; Huo W; Ma Y; Wang X; Yu J
    Cancer Lett; 2024 Sep; 600():217185. PubMed ID: 39142498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for Glioblastoma: Current Progress and Challenges.
    Yu MW; Quail DF
    Front Immunol; 2021; 12():676301. PubMed ID: 34054867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crosstalk Between Tumor-Associated Microglia/Macrophages and CD8-Positive T Cells Plays a Key Role in Glioblastoma.
    Tu S; Lin X; Qiu J; Zhou J; Wang H; Hu S; Yao Y; Wang Y; Deng Y; Zhou Y; Shao A
    Front Immunol; 2021; 12():650105. PubMed ID: 34394072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives.
    Montoya M; Gallus M; Phyu S; Haegelin J; de Groot J; Okada H
    Cells; 2024 Apr; 13(9):. PubMed ID: 38727262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments.
    Feldman L
    Front Immunol; 2024; 15():1384249. PubMed ID: 38994360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GBM immunotherapy: Exploring molecular and clinical frontiers.
    Ghosh MK; Kumar S; Begam S; Ghosh S; Basu M
    Life Sci; 2024 Nov; 356():123018. PubMed ID: 39214286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update.
    Alsajjan R; Mason WP
    Curr Oncol; 2023 Sep; 30(9):8501-8549. PubMed ID: 37754534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
    O'Rourke DM; Nasrallah MP; Desai A; Melenhorst JJ; Mansfield K; Morrissette JJD; Martinez-Lage M; Brem S; Maloney E; Shen A; Isaacs R; Mohan S; Plesa G; Lacey SF; Navenot JM; Zheng Z; Levine BL; Okada H; June CH; Brogdon JL; Maus MV
    Sci Transl Med; 2017 Jul; 9(399):. PubMed ID: 28724573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: The State-of-Art in Immuno-Oncology, What to Do With Glioblastoma?
    Cui X; Wang Q; Kang C
    Front Immunol; 2021; 12():788733. PubMed ID: 34777399
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunotherapy drives mesenchymal tumor cell state shift and TME immune response in glioblastoma patients.
    Hendriksen JD; Locallo A; Maarup S; Debnath O; Ishaque N; Hasselbach B; Skjøth-Rasmussen J; Yde CW; Poulsen HS; Lassen U; Weischenfeldt J
    Neuro Oncol; 2024 Aug; 26(8):1453-1466. PubMed ID: 38695342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
    Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
    Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Mechanisms of Treatment Resistance in Glioblastoma.
    Ou A; Yung WKA; Majd N
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
    Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():582106. PubMed ID: 33178210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of Glioblastoma: Current Strategies and Challenges in Tumor Model Development.
    Majc B; Novak M; Kopitar-Jerala N; Jewett A; Breznik B
    Cells; 2021 Jan; 10(2):. PubMed ID: 33572835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy.
    Salinas RD; Durgin JS; O'Rourke DM
    CNS Drugs; 2020 Feb; 34(2):127-145. PubMed ID: 31916100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment.
    Kwok D; Okada H
    J Neurooncol; 2020 Apr; 147(2):281-295. PubMed ID: 32185647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local Targeting of NAD
    Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
    Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.